- Update to our [FDA-Approved Oncology Therapies](https://www.oncokb.org/oncology-therapies) page
- Update to our [FDA Cleared or Approved Companion Diagnostic Devices](https://www.oncokb.org/companion-diagnostic-devices) (CDx) page
- Key updates to the functional classification and variant-level annotation of the _NPM1_ gene
  - _NPM1_ updated from Tumor Suppressor gene (TSG) to both Oncogene (OG) and TSG
  - Biological effect of annotated variants updated from Loss-of-function to Switch-of-function

**Updated Therapeutic Implications**

- Promotion of tumor type-specific level of evidence for an alteration

| Gene | Mutation                                                                                                                                                                                                                                                                                                                              | Cancer Type            | Level-associated Drug(s) in OncoKB™                                                                                                | Previous Level | Updated Level | Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| :--- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | :--------------------- | :--------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| ESR1 | V422del                                                                                                                                                                                                                                                                                                                               | Breast Cancer          | _Drug(s) added to OncoKB™:_ Imlunestrant (Level 1\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Elacestrant (Level 2\)                | 2              | 1             | [FDA approval of imlunestrant](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast); PMID: [39660834](https://www.ncbi.nlm.nih.gov/pubmed/39660834)                                                                                                                                                                                                                                                    |
| ESR1 | S463F                                                                                                                                                                                                                                                                                                                                 | Breast Cancer          | _Drug(s) added to OncoKB™:_ Imlunestrant (Level 1\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Fulvestrant (Level 3A)                | 3A             | 1             | [FDA approval of imlunestrant](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast); PMID: [39660834](https://www.ncbi.nlm.nih.gov/pubmed/39660834)                                                                                                                                                                                                                                                    |
| NPM1 | Susceptible NPM1 mutations per the FDA label: Exon 5 truncating mutations, Exon 9 truncating mutations, Exon 11 truncating mutations Select exon 5 indels: K134delinsQLLSGL, L135insALELGN, L136_137insAEDVKLL, K141_142insLSALSISGK Select NPM1 fusions: NPM1-CCDC28A Fusion, NPM1-HAUS1 Fusion, NPM1-MLF1 Fusion, NPM1-RPP30 Fusion | Acute Myeloid Leukemia | _Drug(s) added to OncoKB™:_ Ziftomenib (Level 1\)<br/><br/>_Drug(s) promoted in OncoKB™:_ Revumenib (Level 1, previously Level 3A) | 3A             | 1             | [FDA approval of revumenib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation?); PMID: [40332046](https://pubmed.ncbi.nlm.nih.gov/40332046/)<br/><br/>[FDA approval of ziftomenib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation?); PMID: [40997296](https://pubmed.ncbi.nlm.nih.gov/40997296/) |

- Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)

| Level | Gene | Mutation                                                                                  | Cancer Type   | Level-Associated Drug(s) in OncoKB™ | Drug(s) Added to OncoKB™ | Evidence                                                                                                                                                                                                                                                      |
| :---- | :--- | :---------------------------------------------------------------------------------------- | :------------ | :---------------------------------- | :----------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| 1     | ESR1 | Activating ligand-binding domain missense mutations: S463P, L469V, L536, Y537, D538, E380 | Breast Cancer | Elacestrant (Level 1\)              | Imlunestrant (Level 1\)  | [FDA approval of imlunestrant](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast); PMID: [39660834](https://www.ncbi.nlm.nih.gov/pubmed/39660834) |

- Addition of 10 new genes:
  - AIM2
  - AURKC
  - CAV1
  - COL5A1
  - GSTO1
  - HERPUD1
  - LZTS1
  - PICALM
  - PTK7
  - YWHAE
